SecBot SecBot
8-K ·Filed Mar 4, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 5/10
Horizondays Processed8mo ago SEC0001664710-26-000017
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

LLM returned non-JSON response. Review the filing manually.

DirectionNeutral
Confidencelow
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.71
T+0 close · Mar 4, 2026 · via day close
Latest settled
−6.92%
T+60 · $10.90
Vs SPY
−18.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $11.71entry
  2. T+1 · 9mo ago −3.50%α −2.19% · $11.30
  3. T+5 · 8mo ago −6.15%α −3.91% · $10.99
  4. T+20 · 8mo ago +2.48%α +6.27% · $12.00
  5. T+60 · 6mo ago −6.92%α −18.22% · $10.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

{ "summary": "Keros Therapeutics reported a full-year net income of $87.0 million for 2025, a significant improvement from a $187.4 million net loss in 2024, primarily due to $205.4 million in license revenue from Takeda. The company also announced leadership changes and upcoming clinical trial milestones for rinvatercept in DMD and ALS. Cash reserves declined to $287.4 million from $559.9 million, largely due to a share repurchase and tender offer.", "sentiment": "mixed", "impactScore": 6

Financial Impact

Unknown

Risk Factors

  • Analysis may be incomplete

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001664710-26-000017
Document: kros-20260304.htm0001664710-26-000017
Document: 0001664710-26-000017-index-headers.html0001664710-26-000017
Document: 0001664710-26-000017-index.html0001664710-26-000017
Document: 0001664710-26-000017.txt0001664710-26-000017

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 4, 2026